This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Charrow et al¹ have made sound suggestions for the diagnosis of Gaucher disease, but their recommendations for follow-up of patients diagnosed as having Gaucher disease require serious scrutiny. The performance of diagnostic procedures costing more than $4500 every year or two should be based on evidence. The authors state that they have based their recommendations on the medical literature and their own experience. Unfortunately, the principal literature that deals with the natural history of the disease is not cited, and the experience of the directors of International Collaborative Gaucher Group Registry is limited in scope and duration; this organization was established only a few years ago by Genzyme Corporation (Cambridge, Mass), the manufacturer of Ceredase and Cerezyme.

During the past 30 years I have personally followed more than 200 patients with Gaucher disease, some of them for periods exceeding 25 years. This experience has taught me how indolent this disease . . . [Full Text of this Article]

RELATED ARTICLE

Gaucher Disease: Recommendations on Diagnosis, Evaluation, and Monitoring
Joel Charrow, Joan A. Esplin, T. John Gribble, Paige Kaplan, Edwin H. Kolodny, Gregory M. Pastores, C. Ronald Scott, Rebecca S. Wappner, Neal J. Weinreb, and Jeffrey S. Wisch
Arch Intern Med. 1998;158(16):1754-1760.
ABSTRACT | FULL TEXT